### Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/oo, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$ 

| Name  | of entity  |  |
|-------|--|--|
| Cerar | nic Fuel Cells Limited   |  |
| ABN   |  |  |
| 82 05 | 5 736 671  |  |
| We (t | he entity) give ASX the following  | g information.   |
|       | 1 - All issues ust complete the relevant sections (attac   | h sheets if there is not enough space).                |
| 1     | *Class of *securities issued or to<br>be issued  | Convertible Security (Convertible Security)            |
|       |  |  |
| 2     | Number of *securities issued or<br>to be issued (if known) or<br>maximum number which may<br>be issued | Convertible Security with a face value of US\$450,000. |

<sup>+</sup> See chapter 19 for defined terms.

**Principal** the terms of 3 +securities (e.g. if options, exercise price and expiry date; if paid +securities, amount outstanding and due dates for if payment; +convertible securities, the conversion price and dates for conversion)

#### Convertible Security

- The face value of the Convertible Security is US\$450,000 (the *Principal Amount*).
- The Convertible Security does not bear interest.
- The Convertible Security shall be convertible into new Ordinary Shares of the Company determined by dividing the Principal Amount by the lesser of:

   (a) 90% of the average of the three daily VWAPs per share during a specified period prior to the conversion date of the Convertible Security; and
  - (b) 130% of the average of the daily VWAPs per share during the 20 trading days prior to 24 March 2014, being A\$0.0378.
- The Ordinary Shares issued upon conversion of the Convertible Security will rank pari passu with existing Ordinary Shares.
- The Convertible Security does not carry any voting rights at meetings of shareholders of the Company, and has no rights of participation in any rights issues undertaken by the Company prior to their conversion.
- 4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

On conversion of the Convertible Security, the Ordinary Shares will rank *pari passu* with existing Ordinary Shares.

5 Issue price or consideration

US\$350,000 for the Convertible Security.

Purpose of the issue The purpose of the issue of the Convertible Security is to 6 (If issued as consideration for raise capital for general corporate and working capital the acquisition of assets, clearly purposes. The Convertible Security is issued pursuant to the Share Purchase and Convertible Security Agreement, identify those assets) details of which were announced to the market on 24 March 2014. 6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b -6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was passed 6c Number of \*securities issued n/a without security holder approval under rule 7.1 6d Number of \*securities issued n/a with security holder approval under rule 7.1A 6e Number of \*securities issued with security holder approval under rule 7.3, or another specific security holder (specify date approval of meeting) 6f Number of \*securities issued under an exception in rule 7.2 n/a 6g If \*securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the **VWAP** source of the calculation.

<sup>+</sup> See chapter 19 for defined terms.

| 6h | If +securities were | issued under | r |
|----|---------------------|--------------|---|
|    | rule 7.1A for       | non-cash     |   |
|    | consideration, sta  | te date on   |   |
|    | which valuat        | tion of      | ' |
|    | consideration was   | released to  |   |
|    | ASX Market Annou    | incements    |   |

| n/a |  |  |  |
|-----|--|--|--|
|     |  |  |  |
|     |  |  |  |
|     |  |  |  |
|     |  |  |  |
|     |  |  |  |

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

243,717,236 under Rule 7.1

plus

239,259,026 under Rule 7.1A

equals

482,976,262 Total

#### 7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

| 2 July 2014 |  |  |  |
|-------------|--|--|--|
|             |  |  |  |
|             |  |  |  |

8 Number and \*class of all \*securities quoted on ASX (*including* the \*securities in section 2 if applicable)

| Number        | +Class   |
|---------------|----------|
| 2,507,761,565 | Ordinary |
|               | Shares   |
|               |          |
|               |          |
|               |          |
|               |          |
|               |          |

9 Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

| Number     | +Class                      |
|------------|-----------------------------|
| 24,800,000 | Options exercisable at      |
|            | \$0.0378 on or before       |
|            | 24 March 2018.              |
| and        |                             |
| 4,100,000  | convertible loan notes      |
|            | with a face value of        |
|            | £4,100,000                  |
| and        |                             |
| 1          | Convertible Security with   |
|            | a face value of US\$375,000 |
| and        |                             |
| 1          | Convertible Security with   |
|            | a face value of US\$450,000 |
| and        |                             |
| 8,260,650  | options                     |
|            | (refer Annexure 2)          |

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

n/a

### Part 2 - Pro rata issue

| 11 | Is security holder approval required?  | n/a |
|----|--|-----|
| 12 | Is the issue renounceable or non-renounceable?   | n/a |
| 13 | Ratio in which the *securities will be   | n/a |
|    | offered  |     |
| 14 | <sup>+</sup> Class of <sup>+</sup> securities to which the offer relates                           | n/a |
| 15 | <sup>+</sup> Record date to determine entitlements   | n/a |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | n/a |
| 17 | Policy for deciding entitlements in  | n/a |
| ,  | relation to fractions  |     |

<sup>+</sup> See chapter 19 for defined terms.

| 18  | has security holders who will not be sent new offer documents   | n/a   |
|-----|---|-------|
|     | Note: Security holders must be told how their entitlements are to be dealt with.  |       |
|     | Cross reference: rule 7.7.  |       |
| 19  | Closing date for receipt of acceptances or renunciations  | n/a   |
| 20  | Names of any underwriters   | n/a   |
|     |   |       |
| 21  | Amount of any underwriting fee or commission  | n/a   |
| 22  | Names of any brokers to the issue   | n/a   |
|     | ,   |       |
|     |   |       |
| 23  | Fee or commission payable to the broker to the issue  | n/a   |
| 2.4 | Amount of any handling for navable to   | n/2   |
| 24  | Amount of any handling fee payable to<br>brokers who lodge acceptances or<br>renunciations on behalf of security<br>holders | n/a   |
|     |   |       |
| 25  | If the issue is contingent on security holders' approval, the date of the meeting   | n/a   |
| _   |   |       |
| 26  | Date entitlement and acceptance form<br>and offer documents will be sent to<br>persons entitled                             | n/a   |
|     | If the entity has issued options, and the   | n/a   |
| 27  | terms entitle option holders to<br>participate on exercise, the date on<br>which notices will be sent to option<br>holders  | II/d  |
|     |   |       |
| 28  | Date rights trading will begin (if applicable)  | n/a   |
| 20  | Date rights trading will end (if  | n/a   |
| 29  | applicable)   | 11/ α |
|     |   |       |
| 20  | How do security holders sell their  |       |
| 30  | entitlements in full through a broker?  |       |

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

| 31 | How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?   |    |
|----|---|----|
| 32 | How do security holders dispose of their entitlements (except by sale through a broker)?  |    |
| 33 | <sup>+</sup> Issue date   |    |
|    | Part 3 - Quotation of securities  You need only complete this section if you are applying for quotation of securities   |    |
|    | Type of *securities (tick one)  |    |
|    | (a) +Securities described in Part 1   |    |
|    | (b) All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully pa employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertil securities |    |
|    | Entities that have ticked box 34(a)  Additional securities forming a new class of securities  |    |
|    | Tick to indicate you are providing the information or documents   |    |
|    | If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders   |    |
|    | If the *securities are *equity securities, a distribution schedule of the addition *securities setting out the number of holders in the categories  1 - 1,000  1,001 - 5,000  5,001 - 10,000  10,001 - 100,000  100,001 and over                                      | al |
|    | A copy of any trust deed for the additional *securities   |    |

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b) 38 Number of \*securities for which <sup>+</sup>quotation is sought +Class of +securities for which 39 quotation is sought Do the \*securities rank equally in 40 all respects from the +issue date with an existing +class of quoted \*securities? If the additional +securities do not rank equally, please state: the date from which they do the extent to which they participate for the dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution interest or payment Reason for request for quotation 41 now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another \*security, clearly identify that other +security) Number +Class

Number

38)

+securities

42

and +class of all

quoted on

(including the +securities in clause

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 4 July 2014

(Director/Company Secretary)

Print name: Glenn Raines

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

| Rule 7.1 – Issues ex   | ceeding 15% of capital  |
|--|---|
| Step 1: Calculate "A", the base figures capacity is calculated   | ure from which the placement  |
| Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue   | 1,591,941,620   |
| Add the following:   |   |
| Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2  | 9,345,794 (Oct 2013 Convertible Loan<br>Notes conversion)   |
| Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval   | 109,302,848 (Dec 2013 Share Purchase Plan)<br>10,000,000 (Mar 2014 Bergen Shares)<br>672,000,000 (Apr 2014 Share Placement) |
| Number of partly paid <sup>+</sup> ordinary<br>securities that became fully paid in that<br>12 month period  | 0   |
| Note: Include only ordinary securities here — other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items |   |
| <b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period  | 0   |
| "A"  | 2,392,590,262   |

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

| Step 2: Calculate 15% of "A"   |  |
|--|--|
| "B"  | 0.15 [Note: this value cannot be changed]  |
| <b>Multiply</b> "A" by 0.15  | 358,888,539  |
| Step 3: Calculate "C", the amount of that has already been used  | of placement capacity under rule 7.1   |
| <ul> <li>Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> | 41,134,062 Shares (Dec 2013 Overseas Offer)<br>9,800,000 Shares (Mar 2014 Bergen)<br>13,406,250 Shares (Apr 2014 Bergen)<br>21,677,900 Shares (May 2014 Bergen)<br>29,153,091 Shares (Jun 2014 Bergen) |
| "C"  | 115,171,303  |
| Step 4: Subtract "C" from ["A" x "E capacity under rule 7.1  | 3"] to calculate remaining placement   |
| "A" x 0.15<br>Note: number must be same as shown in<br>Step 2  | 358,888,539  |
| Subtract "C"  Note: number must be same as shown in Step 3   | 115,171,303  |
| <i>Total</i> ["A" x 0.15] – "C"  | 243,717,236 [Note: this is the remaining placement capacity under rule 7.1]  |

<sup>+</sup> See chapter 19 for defined terms.

| Step 1: Calculate "A", the base figu   | re from which the placement        |
|--|------------------------------------|
| "A" Note: number must be same as shown in  | 2,392,590,262                      |
| Step 1 of Part 1   |                                    |
| Step 2: Calculate 10% of "A"   |                                    |
| "D"  | 0.10                               |
|  | Note: this value cannot be changed |
| <b>Multiply</b> "A" by 0.10  | 239,259,026                        |
| 7.1A that has already been used  |                                    |
| <b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A | 0                                  |
| or agreed to be issued in that 12 month  | 0                                  |

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

| Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A |  |  |  |  |
|---|--|--|--|--|
| "A" x 0.10  | 239,259,026  |  |  |  |
| Note: number must be same as shown in Step 2  |  |  |  |  |
| Subtract "E"  | 0  |  |  |  |
| Note: number must be same as shown in Step 3  |  |  |  |  |
| <b>Total</b> ["A" x 0.10] – "E"   | 239,259,026  |  |  |  |
|   | Note: this is the remaining placement capacity under rule 7.1A |  |  |  |

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B

### Annexure 2

### Ceramic Fuel Cells Limited securities not quoted on ASX

Share Options issued under the CFCL Share Option Plan and Directors and Employee Benefits Plan as at 4 July 2014

| Grant Date              | Expiry Date | Exercise price<br>A \$ | Balance at<br>4 July 2014 | Exercisable at<br>4 July 2014 |
|-------------------------|-------------|------------------------|---------------------------|-------------------------------|
| 1 Sep 2004              | 31 Aug 2014 | 0.76                   | 30,000                    | 30,000                        |
| 12 Oct 2005             | 11 Oct 2015 | 0.57                   | 123,250                   | -                             |
| 24 Aug 2006             | 23 Aug 2016 | 0.58                   | 199,200                   | 199,200                       |
| 29 Aug 2007             | 28 Aug 2017 | 1.01                   | 756,210                   | 756,210                       |
| 28 Mar 2008             | 27 Mar 2018 | 0.45                   | 690,400                   | 690,400                       |
| 28 Aug 2008             | 27 Aug 2018 | 0.44                   | 1,118,430                 | 1,118,430                     |
| 26 Jun 2009             | 25 Jun 2019 | 0.175                  | 1,731,710                 | 1,731,710                     |
| 1 Oct 2010              | 30 Sep 2020 | 0.1825                 | 1,439,700                 | 1,439,700                     |
| 28 Sep 2011             | 27 Sep 2021 | 0.15                   | 2,171,750                 | 2,171,750                     |
| Total Number of Options |             |                        | 8,260,650                 | 8,137,400                     |

Appendix 3B Page 14 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.